期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

间接酶联免疫吸附试验测定恶性肿瘤血清中核糖核酸酶抑制因子表达的研究 被引量：1

Expression of ribonuclease inhibitor in serum of patients with malignant tumors detected by indirect ELISA
下载PDF
导出
摘要 目的:探讨间接酶联免疫吸附试验(ELISA)检测核糖核酸酶抑制因子(RI)在恶性肿瘤患者血清中的表达。方法:建立检测血清RI含量的间接ELISA法,检测和比较正常人、恶性肿瘤患者(乳腺癌、胃癌、肺癌、肝癌)、乳腺良性肿瘤患者血清中RI的表达水平。结果:所建立的间接ELISA法特异性高;恶性肿瘤患者血清中RI表达均明显低于正常人(P<0.05),乳腺癌亦明显低于乳腺良性肿瘤(P<0.05)。结论:RI表达的降低可以作为肿瘤良、恶性鉴别的指标之一。 Objective： To detect the expression of ribonuclease inhibitor （RI） in the serum of patients with malignant tumors by indirect ELISA. Methods：The indirect ELISA method was established to detect the expression of RI in the serum of patients with malignant tumors, including breast cancer,gastric cancer,lung cancer,and liver cancer,patients with benign breast tumor,and normal controls. Results：The specificity of the indirect ELISA was high in the detection of the expression of RI. The expression of RI in patients with malignant tumors was significantly lower than that in normal controls. Conclusion：The indirect ELISA is a specific method for detecting the expression of RI,and the expression of RI may be used in the differential diagnosis of malignant and benign tumors.
作者 刘宇 刘基巍 崔秀云
机构地区 大连市第三人民医院肿瘤科 大连医科大学附属第一医院肿瘤科 大连医科大学生物化学和分子生物学教研室
出处 《中国医科大学学报》 CAS CSCD 北大核心 2007年第1期15-16,共2页 Journal of China Medical University
基金 国家自然科学基金资助项目(39870242)
关键词 核糖核酸酶抑制因子 间接酶联免疫吸附试验 恶性肿瘤 ribonuclease inhibitor enzyme-linked immunosorbent assay mallgnant tumor
分类号 R446.61 [医药卫生—诊断学]
  • 相关文献

参考文献8

  • 1舒晓宏,李传刚,张海涛,陈俊霞,田余祥,于丽华,崔秀云.抗核糖核酸酶抑制因子抗体的制备与纯化[J].细胞与分子免疫学杂志,2004,20(5):572-574. 被引量：9
  • 2Li D,Bell J,Berry CL.The observation of angiogenin and basic fibroblast growth factor gene expression in human clonic adenocacinomas,gastric adenocarcinomas,and heptocellular carcinomas[ J ].J Pathol,1994,172(2):171-175.
  • 3Shapiro R.Cytoplasmic ribonuclease inhibitor[J].Methods Enzymol,2001,341 (2):611-628.
  • 4田余祥,王冬梅,崔秀云.人乳腺癌组织中核糖核酸酶抑制因子基因的表达分析[J].癌症,2004,23(3):269-272. 被引量：10
  • 5Desmettre P.Diagnosis and prevention of equine infectious diseases:present status,potential,and challenges for the future[ J ].Adv Vet Med,1999,41 (1):359-377.
  • 6Ravindranath MH,Ravindranath RM,Morton DL.Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA[J].J lmmunol Methods,1994,169(2):257-272.
  • 7段元宏.浅谈ELISA操作中由加样差异造成的OD值偏差[J].中国卫生检验杂志,2002,12(6):749-749. 被引量：5
  • 8Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases[J].Nature,2000,407 (6801):249-257.

二级参考文献15

  • 1崔秀云,张晓晴.恶性肿瘤患者血液中核糖核酸酶及核糖核酸酶抑制因子活性测定[J].肿瘤,1994,14(3):152-154. 被引量：4
  • 2Vallee BL, Riordan JF. Chemical and biochemical properties of human angiogenin [J]. Adv Exp Med Biol, 1988, 234(1): 41-53.
  • 3Lee FS, Vallee BL. Modular mutagenesis of human placental ribonuclease inhibitor, a protein with leucine-rich repeats [J].Proc Nail Acad Sci USA, 1990, 87(5): 1879-1883.
  • 4Lee FS, Shapiro R, Vallee BL. Tight-binding inhibition of angiogenin and fibonuclease A by placental fibonuclease inhibitor[J]. Biochemistry, 1988, 28 (1) : 225-230.
  • 5Polakowski U, Lewis MK, Muthukkaruppan VR. et al. A ribonuelease inhibitor expresses anti-angiogenie properties and leads to reduced tumor growth in mice [J]. Am J Pathol, 1993,143(2): 507-517.
  • 6Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction[J]. Anal Biol, 1987, 162(1): 156-159.
  • 7Lee FS,Vallee BL. Binding of placental ribonuelease inhibitor to the active site of angiogenin [J]. Biochemistry, 1989,28(8):3556-3561.
  • 8Shapiro R. Cytoplasmic ribonuclease inhibitor[J]. Methods Enzymol,2001, 341:611 -628.
  • 9Strydom DJ. Amino acid sequence of human tumor derived angiogenin[J]. Biochemistry, 1985, 24:5486-5494.
  • 10Blackburn P. Ribonuclease Inhibitor from human placenta: rapid purification and assay[J]. J Biol Chem, 1979, 254 ( 24 ): 12484 -12487.

共引文献17

同被引文献23

  • 1Hu L , Magesh S, Chen L, et al. Discovery of a small - molecule inhibitor and cellular probe of Keapl - Nrf2 protein - protein interaction [ J ]. Bioorganic & Medicinal Chemistry Letters, 2013, 23(10) : 3039 -3043.
  • 2Qi J, Kizjakina K, Robinson R, et al. A fluorescence polarization binding assay to identify inhibitors of ilavin - dependent monooxygenases[ J]. Anal Biochem, 2012, 425 (1) : 80 -87.
  • 3Maki J L, Smith E, Teng X, et al. Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1 [ J ]. Anal Biochem, 2012, 427(2) : 164 - 174.
  • 4Lu C W, Liu D, Jin J, et al. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor [ J ]. Biochem Pharmacol, 2013, 85(9) : 1246 - 1256.
  • 5Olaf K, Hyung S P, Justin T E, et al. Development of a potent Bcl- xL antagonist based on a- Helix mimicry[ J]. J Am Chem Soc, 2002, 124(40): 11838 -11839.
  • 6Okamatsu M, Feng F, Ohyanagi T, et al. Fluorescence polarization - based assay using N - glycan - conjugated quantum dots for screening in hemagglutinin blockers for influenza A viruses[J]. J Virol Methods, 2013, 187(2) : 390 - 394.
  • 7Jain R K, HamilLton A D, Protein surface recognition by synthetic receptors based on a tetraphenylporphyfin scaffold[J]. Org Lett, 2000, 2(12) : 1721 - 1723.
  • 8DEB S. P53 Protocols [ M ]. New York: Humana Press Inc. , 2003.
  • 9Mizue Y, Nishihira J, Miyazaki T, et al. Quantitation of macrophage migration inhibitory factor (MIF) using the one- step sandwich enzyme immunosorbent assay: Elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes [ J ]. Int J Mol Med, 2000, 5 (4) : 397 - 403.
  • 10Roberts D W, Pumford N R, Potter D W, et al. A sensitive immunochemical assay for acetaminophen - protein adducts [ J ]. Journal of Pharmacology and Experimental Therapeutics, 1987, 241 (2) : 527 -533.

引证文献1

中国医科大学学报
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部